BNET Industries

Market Cap:$905.1M
Last Fiscal Year Sales:$47.8M
  • Public
  • US
Dow Jones Description

We are a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, or MS, spinal cord injury, or SCI, and other disorders of the central nervous system, or CNS. Our marketed product, Zanaflex Capsules, is approved by the U.S. Food and Drug Administration (FDA) for the management of spasticity. Our lead product candidate, Fampridine-SR, has completed two positive Phase 3 clinical trials for the improvement of walking ability in patients with MS and we submitted a New Drug Application (NDA) to the FDA at the end of January 2009 seeking approval to market it. We have discussed Fampridine-SR with national regulatory authorities in four European Union member states and believe that the current data are sufficient to file a centralized Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA). Our preclinical programs target other aspects of MS, as well as SCI and other CNS disorders, and may also have application for other indications, such as stroke or congestive heart failure. We expect to file an Investigational New Drug (IND) application for Glial Growth Factor 2 (GGF2), the lead product candidate of our neuregulins program, for congestive heart failure in late 2009, pending the successful completion of toxicological and other work.

Chief Executive Officer
Ron Cohen
Number of Employees 174
Contact Information

15 Skyline Drive

Hawthorne, New York 10532

acorda.com

(914) 347-4300

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Zacks Bull and Bear of the Day Highlights: Acorda Therapeutics, Canon, Big Lots, Wal-Mart and...

    11/06/09 - Joint Venture / Alliance - View Story

  • Emerson Electric Net Falls; Cognizant Technology Net Up

    11/03/09 - Financial Announcement - View Story

  • Acorda Therapeutics Reports Third Quarter 2009 Financial Results

    11/03/09 - Mgmt. Change Entering - Vice President - View Story

  • Little Discord on Acorda Drug

    10/15/09 - Joint Venture / Alliance - View Story

  • Early-Market Movers: Solta Medical, Citigroup

    10/15/09 - Bond / Stock Rating - View Story

  • Acorda Therapeutics Gets FDA Advisory Committee OK for Fampridine-SR

    10/20/09 - Product Announcement - View Story

  • Zacks Bull and Bear of the Day Highlights: Acorda Therapeutics, Hain Celestial, Citigroup, US Bancorp...

    9/30/09 - Joint Venture / Alliance - View Story

  • Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR...

    9/14/09 - Joint Venture / Alliance - View Story

  • Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

    8/26/09 - Joint Venture / Alliance - View Story

  • Acorda Therapeutics Reports Second Quarter 2009 Financial Results

    8/04/09 - Financial Announcement - View Story

  • Elan Posts 2Q Financial Results

    7/28/09 - Joint Venture / Alliance - View Story

  • Biogen Idec and Acorda Therapeutics' $500 million-plus deal produces mixed market reaction

    7/06/09 - Bond / Stock Rating - View Story

  • UPDATE: Acorda Shares Fall Following Biogen Deal

    7/01/09 - Bond / Stock Rating - View Story

  • Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

    7/14/09 - Joint Venture / Alliance - View Story

News & Analysis

acorda therapeutics inc. - All News and Analysis

  • Positive FDA Panel Outcome for Acorda Therapeutics

    Seeking Alpha - 2009-10-15

    Mike Havrilla submits: On 4/23/09, Acorda Therapeutics ACOR announced the resubmission of its NDA for Fampridine-SR Amaya to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis (MS) in response to a Refuse to File letter for the NDA issued by the...

    Tags: Biotech, Mike Havrilla, Acorda Therapeutics Inc.

  • Stage Set for Acorda Bounce?

    Seeking Alpha - 2009-10-11

    Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) have hit a five month low, after documents posted on the U.S. Food and Drug Administration's Website show that some agency investigators have questioned whether Acorda's proposed MS treatment Fampridine-SR should be approved. As subscribers to the BioMedReports FDA Calendar know, a special panel...

    Tags: Biotech, Healthcare, M. E. Garza, Acorda Therapeutics Inc., Biogen Idec Inc.

  • Bullish on Acorda: New Drug Looks Promising

    Seeking Alpha - 2009-06-23

    Zacks.com submits: By Jason Napodano, CFA Over the past few months, we have become increasingly confident Acorda Pharmaceuticals' ACOR application for Fampridine-SR looks strong -- from a clinical data standpoint. The application contains data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two phase...

    Tags: Healthcare, Zacks.com, Acorda Therapeutics Inc.

  • Acorda Pops on Good News

    Seeking Alpha - 2009-05-07

    Zacks.com submits: By Jason Napodano, CFA We upgraded shares of Acorda Therapeutics, Inc. ACOR the day after the FDA issued the RTF ("refuse to file") letter on April 1, 2009. At that time the shares were hit hard -- down to the $18 level -- and we noted...

    Tags: Healthcare, Zacks.com, Acorda Therapeutics Inc.

  • FDA Calendar Updates: Acorda, Roche

    Seeking Alpha - 2009-05-06

    Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline...

    Tags: Biotech, Mike Havrilla, Acorda Therapeutics Inc.

Decision Makers

Name (plus bio) Position
Ron Cohen Chief Executive Officer
Andrew Blight Chief Scientific Officer
David Lawrence Chief Financial Officer
Mary Fisher Chief Operating Officer
Thomas C Wessel Chief Medical Officer
Jane Wasman Executive Vice President, General Counsel
Denise Duca Senior Vice President, Human Resources
John Librie Senior Vice President, Sales and Marketing
Anthony O. Caggiano Vice President, Preclinical Development
Tierney Saccavino Vice President, Corporate Communications
Stephen J. Hoffman Observer
Barclay A. Phillips Director
Mark R.E. Pinney Director

Board of Directors

Name (plus bio) Position
Barclay A. Philips Board of Directors
Barry E. Greene Board of Directors
Ian F. Smith Board of Directors
John Friedman Board of Directors
John P. Kelley Board of Directors
Lorin J. Randall Board of Directors
Michael Steinmetz Board of Directors
Sandra Panem Board of Directors
Standish M. Fleming Board of Directors
Steven M. Rauscher Board of Directors

Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for spinal cord injury, multiple sclerosis and other disorders of the central nervous system. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is Chairman Emeritus and a Director of the Board of the New York Biotechnology Association. He also serves as a member of the Health Care Governing Body and the Emerging Company Section of the Board of the Biotechnology Industry Organization (BIO), and as a member of the Columbia-Presbyterian Health Sciences Advisory Council. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and an inductee into the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.”

Organization Position Status
Acorda Therapeutics, Inc. Chief Executive Officer Current
Acorda Therapeutics, Inc. President Current
Intermixx.Com, Inc. President, CEO, and Founder Current
Acorda Therapeutics, Inc. Founder Current
Zymenex A/S and Company Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Advanced Tissue Sciences, Inc. Principal Former
Biotechnology Industry Organization Chairman Former
Intermixx.Com, Inc. Board of Directors Former
Columbia College M.D. Former
Columbia University College of Physicians and Surgeons M.D. Former
University of Bristol B.S. in Zoology and his Ph Former
Princeton University B.A. Degree Former

Andrew R. Blight, Ph.D. has been our Chief Scientific Officer since January 2004 and previously served as our Executive Vice President, Research and Development from 2000 to 2004, and Vice President from 1998 to 2000. Prior to joining Acorda, Dr. Blight spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. Dr. Blight held prior academic positions at Purdue University and New York University. Dr. Blight is a leader in SCI pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials. Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the NIH NSDA review committee. He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society. Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.

Organization Position Status
Acorda Therapeutics, Inc. Chief Scientific Officer Current
Intermixx.Com, Inc. Research Director and Scientific Advisor Current
Acorda Therapeutics, Inc. Executive Vice President Former
National Neurotrauma Society Secretary, Treasurer and Vice President Former
The University of North Carolina Research Director Former
Intermixx.Com, Inc. Advisor Former
Purdue University Former
New York University Former
National Neurotrauma Society Treasurer Former
University of Bristol Ph.D. In Neurobiology Former
University of Bristol B.Sc. In Zoology Former

David Lawrence, M.B.A. has been our Chief Financial Officer since January 2005. He previously served as our Vice President, Finance from January 2001 through 2004, and Director, Finance from 1999 to 2001. From 1991 to 1999, Mr. Lawrence held several positions for Tel-Air Communications, Inc. including Vice President and Controller. Prior to Tel-Air, he held financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the Board of Directors as Treasurer of The Brian Ahearn Children's Fund.

Organization Position Status
Acorda Therapeutics, Inc. Chief Financial Officer Current
Acorda Therapeutics, Inc. Board of Directors Current
Acorda Therapeutics, Inc. Vice President, Finance Former
Southwestern Bell Manager Former
Iona College M.B.A In Finance Former
Roger Williams College Undergraduate Degree In Accounting Former
Roger Williams College degree in Accounting Former

Organization Position Status
Skinmedica Acne System Chief Executive Officer Current
SkinMedica, Inc. Chief Executive Officer Former
Acorda Therapeutics, Inc. Vice President Former
Cephalon, Inc. Vice President, Strategic Healthcare and Commercial Operations Former
Immunex Corporation Corporate Communications Manager Former

Thomas Wessel, M.D., Ph.D., has been our Chief Medical Officer since November 2008. Prior to joining Acorda, Dr. Wessel served as Senior Vice President of Clinical Research at Sepracor, Inc., leading the central nervous system (CNS) and respiratory medicine development teams. He also served as the medical director for the company's insomnia development program, expanded the company’s clinical development capabilities, initiated several projects based on isomer and metabolite technologies, and participated in various business development activities. Previously, Dr. Wessel worked on several CNS projects at Janssen Pharmaceutica in Europe and the U.S., leading the U.S. regulatory submission team for an Alzheimer’s disease treatment approved by the FDA in 2000. Before working in the pharmaceutical industry, Dr. Wessel held several academic and research positions. Dr. Wessel completed his residency in neurology at New York Hospital and Memorial Sloan-Kettering Cancer Center (Cornell University Medical Center), and is Board Certified in Neurology. He graduated from the University of Munich School of Medicine and completed his postgraduate research in experimental neurobiology at the Max-Planck-Institute for Psychiatry in Martinsried, Germany.

Organization Position Status
Acorda Therapeutics, Inc. Chief Medical Officer Current
Sepracor Inc. Senior Vice President of Clinical Research Former
Janssen Pharmaceutica Former

Jane Wasman, J.D. has been our Executive Vice President, General Counsel and Corporate Secretary since May 2004. From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and, corporate licensing and business development. She served as Staff Vice President, International in 2001 and as Staff Vice President, European Operations—Legal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate General Counsel to the U.S. Senate Committee on Veteran's Affairs. Ms. Wasman graduated Magna Cum Laude from Princeton University and earned her J.D. from Harvard Law School. Ms. Wasman is a member of the Board of Directors of the New York Biotechnology Association.

Organization Position Status
Acorda Therapeutics, Inc. Executive Vice President, General Counsel Current
Schering-Plough Corporation Vice President Former
Acorda Therapeutics, Inc. Corporate Secretary Former
Schering-Plough Corporation Associate General Counsel Former
Harvard Law School J.D. Former
Princeton University Former

Denise Duca Ed.M. has been our Vice President, Human Resources since March 2005. Previously she served as our Executive Director, Human Resources from 2002 to 2005. Ms. Duca previously was Director – Staffing and Development for Carter-Wallace’s New Jersey locations consisting of five major divisions; Consumer Products, Pharmaceutical, Diagnostics, International and Pet Products. Prior to her work with Carter-Wallace, Ms. Duca held human resources management positions at Colgate-Palmolive Co. and Viacom International, Inc. Ms. Duca received her Bachelor’s of Professional Studies from Pace University, an M.A. and Ed.M. in Psychological Counseling from Teachers College, Columbia University, and has been a doctoral candidate in the Organization and Leadership Department at Teachers College, Columbia University

Organization Position Status
Acorda Therapeutics, Inc. Senior Vice President, Human Resources Current
Colgate-Palmolive Company Former
Pace University Bachelor's of Professional Studies Former

Organization Position Status
Acorda Therapeutics, Inc. Senior Vice President, Sales and Marketing Current
Acorda Therapeutics, Inc. Vice President, Sales and Marketing Former
Acorda Therapeutics, Inc. Executive Director Former
Btg Former
Fairleigh Dickinson University B.S. In Medical Technology Former

Anthony O. Caggiano, M.D., Ph.D. has been our Vice President of Preclinical Development since February 2009. He previously served in various roles in the Preclinical and Research & Development departments since joining Acorda in 2001, directing basic research and product development efforts, coordinating external research efforts with academic and commercial collaborations, and collaborating in business development activities. Dr. Caggiano has authored papers in neuroinflammation, injury and recovery, and has been the inventor or co-inventor on multiple Acorda technologies. He also has served as a member of the National Institutes of Health (NIH) neuropharmacology Small Business Innovations Research (SBIR) grants review committee. Prior to joining Acorda, Dr. Caggiano co-founded Remote Diagnostic Imaging, a company that assembled an expert staff of radiologists to provide remote diagnostic services to understaffed hospitals. Dr. Caggiano received his undergraduate degree in interdisciplinary studies of biology, chemistry and psychology from University of Virginia, and his M.D. and Ph.D. in neurobiology from the University of Chicago.

Organization Position Status
Acorda Therapeutics, Inc. Vice President, Preclinical Development Current
National Institutes of Health Board of Directors Former
University of Chicago M.D. Former
University of Virginia Undergraduate Degree In Interdisciplinary Studies Former

Tierney Saccavino has been our Vice President of Corporate Communications since March 2005. She previously served as our Senior Director, Corporate Communications from 2001-2005, Director from 1998-2001. Ms. Saccavino brings over 15 years’ experience in public relations, marketing, and corporate communications activities to her position at Acorda. Before joining Acorda she was the Manager of Corporate Relations at Adventis, a Boston-based management consulting firm focusing on the media, communications and telecom industries. In that capacity, she was responsible for public relations, corporate promotions, and executive education programs. Previously, she worked for nine years in a variety of positions at Fidelity Investments including human resources and information systems. Ms. Saccavino attended the University of Connecticut in Storrs, Connecticut.

Organization Position Status
Acorda Therapeutics, Inc. Vice President, Corporate Communications Current
Adventis Corporation Manager of Corporate Relations Former
University of Connecticut Former

Organization Position Status
Skyline Ventures Managing Director Current
Techno Venture Management General Partner Current
Proteon Therapeutics, LLC General Partner, Tvm Capital Current
Cydex, Inc. Investment Manager Current
Paintedfrog Studio Investment Manager In the Life Science Team Current
Sunol Molecular Corp. Observer Current
Acorda Therapeutics, Inc. Observer Current
Allos Therapeutics, Inc. Chairman Current
Proteon Therapeutics, LLC Board of Directors Current
Concert Pharmaceuticals Board of Directors Current
Genetix Pharmaceuticals, Inc Board of Directors Current
Cydex, Inc. Board of Directors Current
Magen Biosciences, Inc Board of Directors Current
Precision Therapeutics, Inc. Board of Directors Current
Sirtris Pharmaceuticals, Inc. Board of Directors Current
TolerRx, Inc. Board of Directors Current
Paintedfrog Studio Board of Directors Current
Sunol Molecular Corp. Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Allos Therapeutics, Inc. Chief Executive Officer Former
Allos Therapeutics, Inc. President Former
Somatogen, Inc. Vice President Former
Somatogen, Inc. Founder Former
Somatogen, Inc. Director of Corporate Former
Genetix Pharmaceuticals, Inc Chairman of the Board of Directors of Genetix and Former
Allos Therapeutics, Inc. Director Former
Northwestern University Ph.D. In Bio, Organic Chemistry Former
University of Colorado School of Medicine M.D. Former
University of Colorado M.D. Former

Organization Position Status
Acorda Therapeutics, Inc. Board of Directors Current

Barclay A. Phillips, age 46, has served as our Chief Financial Officer since August 2008. Previously, he served as a member of our board of directors from 2000 until his appointment as our Chief Financial Officer in August 2008. From 1999 to August 2008, Mr. Phillips was a Managing Director of Vector Fund Management. From 1991 to 1999, Mr. Phillips served in various roles including Director of Private Placements and Biotechnology Analyst for INVESCO Funds Group, Inc. From 1985 to 1990, Mr. Phillips held positions in sales and trading with Paine Webber, Inc. and Shearson Lehman Hutton, Inc. Over the last ten years, Mr. Phillips has held board positions for a number of public and private companies and currently serves as a director of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company. Mr. Phillips received a B.A. in economics from the University of Colorado in Boulder.

Organization Position Status
Micromet, Inc. Senior Vice President and Chief Financial Officer Current
Vector Fund Management Managing Director Current
Acorda Therapeutics, Inc. Director Current
Micromet, Inc. Member of Cancervax Current
Vector Fund Management Manager Former
Cellomics Inc. Director Former
University of Colorado B.A. in economics Former

Barry Greene is the President and Chief Operating Officer of Alnylam Pharmaceuticals. Barry joined Alnylam in September 2003, bringing over 15 years of experience in healthcare industries and consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's past experiences include Vice president of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business.

Organization Position Status
Alnylam Pharmaceuticals, Inc. President Current
Alnylam Pharmaceuticals, Inc. Chief Operating Officer Current
Duke University, The Fuqua School of Business Senior Scholar Current
Fuqua Store Current
Alnylam Pharmaceuticals, Inc. Board of Directors Current
Global Capital Associates Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Millennium Pharmaceuticals, Inc. General Manager Former
Accenture Ltd. partner Former
Rigid Building Systems Ltd. Former
University of Pittsburgh B.S. In Industrial Engineering Former

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President and Chief Financial Officer Current
Vertex, Inc. Executive Vice President Current
Infinity Pharmaceuticals, Inc Chair Current
Acorda Therapeutics, Inc. Board of Directors Current
TolerRx, Inc. Board of Directors Current
Predix Pharmaceuticals Holdings, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Prohost Biotechnology Board of Directors Current
American Institute of Certified Public Accountants Member Current
Vertex, Inc. Chief Financial Officer Former
Vertex Pharmaceuticals Incorporated Senior Vice President Former
Vertex, Inc. Senior Vice President Former
Vertex, Inc. Vice President Former
Life Science!, Inc Partner Former
Ernst & Young partner Former
Manchester Metropolitan University B.A. with honors in accounting Former

Organization Position Status
Trellis Bioscience, Inc Founder of Easton Capital Investment Group Current
Easton Capital Investment Group Founder Current
Genetix Pharmaceuticals, Inc Managing Partner of Easton Capital Investment Group Current
Easton Capital Investment Group Managing Partner, New York Office Current
Iga Worldwide, Inc. Managing Partner, Easton Capital Current
YM BioSciences Inc. Managing Partner, Easton Hunt Capital Partners Current
Presidents Council Co-Chairman Current
Iga Worldwide, Inc. Board of Directors Current
The New York City Police Foundation Board of Directors Current
New Museum of Contemporary Art Board of Directors Current
Neighborhood Coalition for Shelter, Inc. Board of Directors Current
Genetix Pharmaceuticals, Inc Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Trellis Bioscience, Inc Board of Directors Current
Assistive Technology, Inc. Board of Directors Current
Cardiovascular Systems Inc. Director Current
Xoft, Inc. Board of Directors Current
Easton Capital Investment Group Board of Directors Current
Comverse Technology, Inc. Board Member Current
Conor Medsystems, Inc. Board Member Current
Playspan Inc. Board of Directors Current
Axys Pharmaceuticals Chief Executive Officer Former
Cold Spring Harbor Laboratory President's Council Former
E.M. Warburg Pincus & Co. Managing Director Former
Easton Capital Investment Group Owner Current
Axys Pharmaceuticals Chairman Former
Axys Pharmaceuticals Director Former
YM BioSciences Inc. Board of Directors Current
U.S. Healthcare, Inc. Investor Former
Tweed's, Inc. Investor Former
Yale Law School Jd Degree Former
Yale College BA Degree Former
Yale University B.A. Former
State University of New York at Buffalo B.A. In History Former
Renovis, Inc. member Former
Comverse Technology, Inc. member Former

Organization Position Status
Angiox President and Chief Operating Officer Current
The Medicines Company President and Chief Operating Officer Current
The Medicines Company Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Sanofi-Aventis Senior Vice President, Global Marketing Former
Sanofi-Aventis Senior Vice President, Global Marketing and Medical Former
Sanofi-Aventis Commercial Director Former
Sanofi-Aventis Head of Strategic Development Former
Rockhurst University M.B.A. Former
Wilkes University B.A. Former

Mr. Randall has served as our Director since September 4, 2007. Mr. Randall is an independent financial consultant and previously was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004, Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001, Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publicly-traded manufacturer of semiconductor manufacturing equipment. Mr. Randall currently serves on the boards of directors of Point 5 Technologies, Inc., Rapid Micro Biosystems, Inc., Acorda Therapeutics, Inc. and Opexa Therapeutics, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

Organization Position Status
Athersys, Inc. Board of Directors Current
LP Technologies Board of Directors Current
Opexa Therapeutics, Inc. Board of Directors Current
Acorda Therapeutics, Inc. Board of Directors Current
Eximias Pharmaceutical Corporation Chief Financial Officer Former
Cfm Technologies, Inc. Chief Financial Officer Former
Eximias Pharmaceutical Corporation Senior Vice President Former
Cfm Technologies, Inc. Vice President Former
Quadsystems Board of Directors Former
Northeastern University M.B.A. Former
The Pennsylvania State University B.S. In Accounting Former

Organization Position Status
Intermixx.Com, Inc. Chief Financial Officer and Director Current
Tacoda Systems, Inc. Tacoda's Chief Financial Officer Current
Mayfair Securities, LLC Current
Acorda Therapeutics, Inc. Director Current
Lifewire, Inc. Chief Executive Officer Former
Acorda Therapeutics, Inc. Chief Financial Officer Former
Dillon Read Vice President, Private Transactions Former
Merrill Lynch & Co., Inc. Vice President, Corporate Finance Former
Cando Chairman Former
University of Chicago Graduate School of Business M.B.A. Former
University of Chicago M.B.A. Former
Columbia University masters degree in engineering Former
University of Exeter undergraduate degree in engineering Former

Michael Steinmetz, PhD, has been Managing Director of Clarus Ventures since the firm's inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 1997. From 1986 to 1997, Dr. Steinmetz was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology. Dr. Steinmetz obtained his Ph.D. summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology. Dr. Steinmetz represents Clarus Ventures on the Board of Directors of ESBATech and Oxford Immunotec. In addition he is a member of the Board of Directors of Amphora, Biovitrum (STO:BVT), BioXell (SWX: BXLN), CGI Pharmaceuticals, ISB Accelerator, Macrogenics, Taigen ,and VLST Corp.

Organization Position Status
Clarus Ventures, LLC Managing Director Current
Bioxell Co-Founder Current
MPM Capital Limited Partnership Affiliate General Partner Current
Vlst Corp Affiliate General Partner, Mpm Capital Current
Homestead Clinical Corporation Board of Directors Current
Heptares Therapeutics Director Current
Intracel Corporation Director Current
CGI Pharmaceuticals, Inc. Board of Directors Current
Allozyne, Inc. Board of Directors Current
Oxford Immunotec Ltd. Board of Directors Current
Bioxell Board of Directors Current
Cellular Genomics Director Current
Acorda Therapeutics, Inc. Board of Directors Current
Biovitrum Director Current
Vlst Corp Board of Directors Current
Clarus Ventures, LLC Board of Directors Current
Macrogenics, Inc. Director Current
Hoffmann-La Roche Inc. Executive Former
Hoffmann, Inc. Executive Former
Roche Former
Pharmacia Corporation Former
Pfizer Inc. Former
Incyte Corporation Former
Accelerator Corporation Chairman Former
Amphora Discovery Corporation Director Former
University of Munich Ph.D. Former
University Corp. Ph.D. Former
University of Hamburg degree in chemistry Former

Sandra Panem joined Cross Atlantic Partners in 2000 as a Managing Partner. Previously, she was President of Vector Fund Management, where she was responsible for the start-up, capital raising, and management of the asset management affiliate of Vector Securities International. Operations included the management of the Vector Later-Stage Equity Fund, L.P., and Vector Later-Stage Equity Fund II, L.P., private partnerships committing $240 million to equity investments in the emerging life science and healthcare industries. Prior to joining Vector, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a $200 million mutual fund that invested in public and private biotechnology companies. Prior to Oppenheimer, Dr. Panem was Vice President at Salomon Brothers, Inc. where she acted as a member of Salomon Brothers Venture Capital, a $40 million fund focused on early and later-stage life science and technology investments. Dr. Panem was also an Assistant Professor at the University of Chicago and a Fellow at the Brookings Institution, and is the author of several books and papers concerning the commercialization of new medical technologies. Currently, she holds directorships in Acorda Therapeutics, Labcyte, and GenomeQuest. She is a director of the New York Biotechnology Association. She received a B.S. Degree in Biochemistry ('66) and a Ph.D. in Microbiology ('70) from the University of Chicago.

Organization Position Status
Cross Atlantic Partners Managing Partner Current
New York Academy of Sciences Governor Current
Airlogix Corporation Current
Martek Biosciences Corporation Board of Directors Current
Intermixx.Com, Inc. Board of Directors Current
Society for Women's Health Research Treasurer Current
Acorda Therapeutics, Inc. Board of Directors Current
The Isis Fund Treasurer Current
Genomequest, Inc. Board of Directors Current
Bioject Medical Technologies Inc. Board of Directors Current
Confluent Surgical, Inc. Board of Directors Current
Labcyte, Inc. Director Current
Vector Fund Management President Former
Salomon Brothers Vice President Former
Salomon Brothers, Inc. Vice President Former
Salomon Brothers Inc. Vice President Former
The Brookings Institution Fellow Former
University of Chicago Professor Former
Vector Corporation Former
University of Chicago Ph.D. In Microbiology Former
University of Chicago B.S. Degree In Biochemistry Former

Organization Position Status
Acorda Therapeutics, Inc. Board of Directors Current
Ambit Biosciences Corporation Board of Directors Current
Tandem Medical, Inc. Director Current
Sanarus Medical, Inc. Director Current
Ambit Corporation Director Current
Nereus, Inc. Director Current
Kemia, Inc. Director Current
Ambit Biosciences Corporation Managing Member, Forward Ventures Current
Triangle Pharmaceuticals, Inc. CEO Former
Triangle Pharmaceuticals, Inc. President Former
Forward Ventures Co-Founder Former
Forward Ventures Owner Former
GSK Biologicals Seattle Former
CombiChem, Inc. Former
Ciphergen Biosystems, Inc. Former
Gilead Sciences, Inc. Former
Triangle Pharmaceuticals, Inc. Director Current
UCLA Anderson School of Management M.B.A. Former
Amherst College B.A. Former

Steven M. Rauscher, CEO , Oscient Pharmaceuticals, has been a Director for TDI since September 2000. After 7 years of service as an outside board of director and President of Genome Therapeutics he assumed the CEO role, morphing GTC into Oscient Pharmaceuticals. Prior to GTC, Mr. Rauscher was most recently CEO of AmericasDoctor, a company formed from the merger of Affiliated Research Centers, Inc. and AmericasDoctor.com. The company provides clinical research and marketing services to the pharmaceutical industry. During his tenure at AmericasDoctor, company revenues grew from $500,000 to more than $56 million, and the company today has nearly 300 employees. Previously, Mr. Rauscher spent over 15 years with Abbott Laboratories serving in a variety of progressive leadership positions, including Vice President for Corporate Licensing; Vice President of Business Development, Abbott International; Vice President of Sales U.S., Pharmaceutical Products; Director of Strategic Planning, Pharmaceutical Products; and General Manager, Abbott West Indies. Mr. Rauscher holds a MBA from University of Chicago.

Organization Position Status
Oscient Pharmaceuticals Corp. CEO Current
Acorda Therapeutics, Inc. Board of Directors Current
Target Discovery, Inc. Director Current
Oscient Pharmaceuticals Corp. Board of Directors Current
Americasdoctor CEO Former
Abbott Laboratories Vice President Former
Americasdoctor Director Former
University of Chicago MBA Former
Indiana University B.S. Former

Executive News

  • Who Was First at the North Pole?

    New York Times - 9/07/09 - View Story

  • Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

    WebWire - 9/02/09 - View Story

  • Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the...

    Reuters - 9/02/09 - View Story

  • Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S.

    PR Newswire - 9/02/09 - View Story

  • The Medicines Company Announces New Publication of Data Showing Angiomax(R) Reduces Cardiac Mortality and Improves

    Reuters - 8/31/09 - View Story

  • The Medicines Company Announces New Publication of Data Showing

    Market Wire via MSN Money - 8/31/09 - View Story

  • Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results

    Business Wire - 8/06/09 - View Story

  • Alnylam and Tekmira Participate in New Research Collaboration

    Forbes.com - 8/06/09 - View Story

  • Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development

    Business Wire - 8/05/09 - View Story

advertisement
     ACOR $23.78 +0.32 (1.36% )
Average Volume 1,085,280
Shares Outstanding 38.06M
Market Cap 905.2M
Year High 29.27
Year Low 14.42
Earnings Per Share -2.19
P/E Ratio -10.86
Dividend N/A
Yield N/A
advertisement